Optimizing Use of Colistin and Polymyxin B in the Critically Ill

Roger L. Nation; Jian Li

doi:10.1055/s-2007-996407

Seminars in Respiratory and Critical Care Medicine, Inhaltsverzeichnis

Semin Respir Crit Care Med 2007; 28(6): 604-614
DOI: 10.1055/s-2007-996407

Optimizing Use of Colistin and Polymyxin B in the Critically Ill

Roger L. Nation¹ , Jian Li¹

¹Facility for Anti-Infective Drug Development and Innovation, Victorian College of Pharmacy, Monash University, Parkville, Victoria, Australia

Abstract

ABSTRACT

Polymyxin B and colistin are being used increasingly for the treatment of infections caused by gram-negative bacteria that are resistant to all other currently available antibiotics. Although the polymyxins have been available in the clinic for around 50 years, they have never been subjected to the drug development procedures required of modern pharmaceuticals. As a result, the available knowledge on the pharmacokinetics (PK), pharmacodynamics (PD), and toxicodynamics (TD) of the polymyxins is limited. Although significant advances have been made in the last 5 years or so, there are still large gaps in our understanding of the PK, PD, and TD, and of the PK/PD and PK/TD relationships. This information is required to generate recommendations on dosage regimens for various categories of critically ill patients. This paper reviews the growing understanding of the pharmacology of the polymyxins and factors that may impact on the optimization of the dose of these antibiotics in critically ill patients.

KEYWORDS

Colistin - polymyxin B - Acinetobacter - Pseudomonas - clinical pharmacology - critically-ill patients

Volltext

Referenzen

REFERENCES

1 Li J, Nation R L, Milne R W, Turnidge J D, Coulthard K. Evaluation of colistin as an agent against multi-resistant gram-negative bacteria. Int J Antimicrob Agents. 2005; 25 11-25
2 Hancock R E. Peptide antibiotics. Lancet. 1997; 349 418-422
3 Elwood C M, Lucas G D, Muehrcke R C. Acute renal failure associated with sodium colistimethate treatment. Arch Intern Med. 1966; 118 326-334
4 Brown J M, Dorman D C, Roy L P. Acute renal failure due to overdosage of colistin. Med J Aust. 1970; 2 923-924
5 Koch-Weser J, Sidel V W, Federman E B, Kanarek P, Finer D C, Eaton A E. Adverse effects of sodium colistimethate: manifestations and specific reaction rates during 317 courses of therapy. Ann Intern Med. 1970; 72 857-868
6 Duncan D A. Colistin toxicity. Neuromuscular and renal manifestations: two cases treated by hemodialysis. Minn Med. 1973; 56 31-35
7 Bad bugs, no drugs. Infectious Diseases Society of America; 2004. http://www.idsociety.org/badbugsnodrugs.html Accessed November 16, 2007
8 Livermore D M. The threat from the pink corner. Ann Med. 2003; 35 226-234
9 Livermore D M. The need for new antibiotics. Clin Microbiol Infect. 2004; 10(Suppl 4) 1-9
10 Talbot G H, Bradley J, Edwards Jr J E, Gilbert D, Scheld M, Bartlett J G. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin Infect Dis. 2006; 42 657-668
11 Gales A C, Jones R N, Sader H S. Global assessment of the antimicrobial activity of polymyxin B against 54731 clinical isolates of gram-negative bacilli: report from the SENTRY antimicrobial surveillance programme (2001-2004). Clin Microbiol Infect. 2006; 12 315-321
12 Sueke H, Marsh H, Dhital A. Using intrathecal colistin for multidrug resistant shunt infection. Br J Neurosurg. 2005; 19 51-52
13 Reina R, Estenssoro E, Saenz G et al.. Safety and efficacy of colistin in Acinetobacter and Pseudomonas infections: a prospective cohort study. Intensive Care Med. 2005; 31 1058-1065
14 Quinn A L, Parada J P, Belmares J, O'Keefe J P. Intrathecal colistin and sterilization of resistant Pseudomonas aeruginosa shunt infection. Ann Pharmacother. 2005; 39 949-952
15 Obritsch M D, Fish D N, Maclaren R, Jung R. Nosocomial infections due to multidrug-resistant Pseudomonas aeruginosa: epidemiology and treatment options. Pharmacotherapy. 2005; 25 1353-1364
16 Mubareka S, Rubinstein E. Aerosolized colistin for the treatment of nosocomial pneumonia due to multidrug-resistant gram-negative bacteria in patients without cystic fibrosis. Crit Care. 2005; 9 29-30
17 Michalopoulos A, Kasiakou S, Rosmarakis E, Falagas M. Cure of multidrug-resistant Acinetobacter baumannii bacteraemia with continuous intravenous infusion of colistin. Scand J Infect Dis. 2005; 37 142-145
18 Michalopoulos A S, Tsiodras S, Rellos K, Mentzelopoulos S, Falagas M E. Colistin treatment in patients with ICU-acquired infections caused by multiresistant gram-negative bacteria: the renaissance of an old antibiotic. Clin Microbiol Infect. 2005; 11 115-121
19 Katragkou A, Roilides E. Successful treatment of multidrug-resistant Acinetobacter baumannii central nervous system infections with colistin. J Clin Microbiol. 2005; 43 4916-4917
20 Kasiakou S K, Rafailidis P I, Liaropoulos K, Falagas M E. Cure of post-traumatic recurrent multiresistant gram-negative rod meningitis with intraventricular colistin. J Infect. 2005; 50 348-352
21 Gump W C, Walsh J W. Intrathecal colistin for treatment of highly resistant Pseudomonas ventriculitis: case report and review of the literature. J Neurosurg. 2005; 102 915-917
22 Falagas M E, Bliziotis I A, Kasiakou S K, Samonis G, Athanassopoulou P, Michalopoulos A. Outcome of infections due to pandrug-resistant (PDR) gram-negative bacteria. BMC Infect Dis. 2005; 5 24
23 Falagas M E, Rizos M, Bliziotis I A, Rellos K, Kasiakou S K, Michalopoulos A. Toxicity after prolonged (more than four weeks) administration of intravenous colistin. BMC Infect Dis. 2005; 5 1
24 Bukhary Z, Mahmood W, Al-Khani A, Al-Abdely H M. Treatment of nosocomial meningitis due to a multidrug resistant Acinetobacter baumannii with intraventricular colistin. Saudi Med J. 2005; 26 656-658
25 Berlana D, Llop J M, Fort E, Badia M B, Jodar R. Use of colistin in the treatment of multiple-drug-resistant gram-negative infections. Am J Health Syst Pharm. 2005; 62 39-47
26 Bratu S, Tolaney P, Karumudi U et al.. Carbapenemase-producing Klebsiella pneumoniae in Brooklyn, NY: molecular epidemiology and in vitro activity of polymyxin B and other agents. J Antimicrob Chemother. 2005; 56 128-132
27 Bratu S, Quale J, Cebular S, Heddurshetti R, Landman D. Multidrug-resistant Pseudomonas aeruginosa in Brooklyn, New York: molecular epidemiology and in vitro activity of polymyxin B. Eur J Clin Microbiol Infect Dis. 2005; 24 196-201
28 Sarria J C, Angulo-Pernett F, Kimbrough R C, McVay C S, Vidal A M. Use of intravenous polymyxin B during continuous venovenous hemodialysis. Eur J Clin Microbiol Infect Dis. 2004; 23 340-341
29 Falagas M E, Kasiakou S K. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis. 2005; 40 1333-1341
30 Li J, Nation R L, Turnidge J D et al.. Colistin: the re-emerging antibiotic for multidrug-resistant gram-negative bacterial infections. Lancet Infect Dis. 2006; 6 589-601
31 Bergen P J, Li J, Rayner C R, Nation R L. Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa . Antimicrob Agents Chemother. 2006; 50 1953-1958
32 Evans M E, Feola D J, Rapp R P. Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria. Ann Pharmacother. 1999; 33 960-967
33 Falagas M E, Kasiakou S K. Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Crit Care. 2006; 10 R27
34 Conway S P, Etherington C, Munday J, Goldman M H, Strong J J, Wootton M. Safety and tolerability of bolus intravenous colistin in acute respiratory exacerbations in adults with cystic fibrosis. Ann Pharmacother. 2000; 34 1238-1242
35 Conway S P, Pond M N, Watson A, Etherington C, Robey H L, Goldman M H. Intravenous colistin sulphomethate in acute respiratory exacerbations in adult patients with cystic fibrosis. Thorax. 1997; 52 987-993
36 Conway S P, Brownlee K G, Denton M, Peckham D G. Antibiotic treatment of multidrug-resistant organisms in cystic fibrosis. Am J Respir Med. 2003; 2 321-332
37 Littlewood J M, Koch C, Lambert P A et al.. A ten year review of Colomycin. Respir Med. 2000; 94 632-640
38 Ledson M J, Gallagher M J, Cowperthwaite C, Convery R P, Walshaw M J. Four years' experience of intravenous colomycin in an adult cystic fibrosis unit. Eur Respir J. 1998; 12 592-594
39 Etherington C, Conway S P, Peckham D G, Bosomworth M. Urinary N-acetyl -b-D-glucosaminidase [NAG] in adults with CF: a marker of nephrotoxicity?. J Cyst Fibros. 2004; 3(Suppl 1) 549 (abstract 180)
40 Al-Aloul M, Miller H, Alapati S, Stockton P A, Ledson M J, Walshaw M J. Renal impairment in cystic fibrosis patients due to repeated intravenous aminoglycoside use. Pediatr Pulmonol. 2005; 39 15-20
41 Garnacho-Montero J, Ortiz-Leyba C, Jimenez-Jimenez F J et al.. Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin Infect Dis. 2003; 36 1111-1118
42 Reed M D, Stern R C, O'Riordan M A, Blumer J L. The pharmacokinetics of colistin in patients with cystic fibrosis. J Clin Pharmacol. 2001; 41 645-654
43 Coly-Mycin M. Parenteral [package insert]. Bristol, TN; Monarch Pharmaceuticals 2005
44 Colomycin injection [summary of product characteristics]. Kent, UK; Forest Laboratories UK Limited 2004
45 Gales A C, Reis A O, Jones R N. Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review of available interpretative criteria and quality control guidelines. J Clin Microbiol. 2001; 39 183-190
46 Clinical and Laboratory Standards Institute .Performance standards for antimicrobial susceptibility testing; fifteenth information supplement (M100-S15). Wayne, PA; Clinical Laboratory Standards Institute 2005
47 Li J, Milne R W, Nation R L, Turnidge J D, Coulthard K. Stability of colistin and colistin methanesulfonate in aqueous media and plasma studied by high-performance liquid chromatography. Antimicrob Agents Chemother. 2003; 47 1364-1370
48 Li J, Coulthard K, Milne R et al.. Steady-state pharmacokinetics of intravenous colistin methanesulphonate in patients with cystic fibrosis. J Antimicrob Chemother. 2003; 52 987-992
49 Li J, Milne R W, Nation R L, Turnidge J D, Smeaton T C, Coulthard K. Pharmacokinetics of colistin methanesulphonate and colistin in rats following an intravenous dose of colistin methanesulphonate. J Antimicrob Chemother. 2004; 53 837-840
50 Li J, Rayner C R, Nation R L et al.. Pharmacokinetics of colistin methanesulfonate and colistin in a critically ill patient receiving continuous venovenous hemodiafiltration. Antimicrob Agents Chemother. 2005; 49 4814-4815
51 Li J, Rayner C R, Nation R L, Owen R J, Tan K E, Spelman D. Hetero-resistance to colistin in multidrug-resistant Acinetobacter baumannii . Antimicrob Agents Chemother. 2006; 50 2946-2950
52 Ebert S C, Craig W A. Pharmacodynamic properties of antibiotics: application to drug monitoring and dosage regimen design. Infect Control Hosp Epidemiol. 1990; 11 319-326
53 Catchpole C R, Andrews J M, Brenwald N, Wise R. A reassessment of the in-vitro activity of colistin sulphomethate sodium. J Antimicrob Chemother. 1997; 39 255-260
54 Tam V H, Schilling A N, Vo G et al.. Pharmacodynamics of polymyxin B against Pseudomonas aeruginosa . Antimicrob Agents Chemother. 2005; 49 3624-3630
55 Owen R J, Li J, Nation R L, Spelman D. In vitro pharmacodynamics of colistin against Acinetobacter baumannii clinical isolates. J Antimicrob Chemother. 2007; 59 473-477
56 Li J, Turnidge J, Milne R, Nation R L, Coulthard K. In vitro pharmacodynamic properties of colistin and colistin methanesulfonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrob Agents Chemother. 2001; 45 781-785
57 Bergen P J, Li J, Nation R L, Turnidge J D, Coulthard K, Milne R W. Is once-daily dosing best for colistin against Pseudomonas aeruginosa? In: Proceedings of the Australian Society for Antimicrobials. Melbourne, Australia; 2007
58 Tan C H, Li J, Nation R L. Pharmacodynamics of colistin against Acinetobacter baumannii in an in vitro PD model and development of resistance. In: Proceedings of the Australian Society for Antimicrobials. Sydney, Australia; 2006
59 Gunderson B W, Ibrahim K H, Hovde L B, Fromm T L, Reed M D, Rotschafer J C. Synergistic activity of colistin and ceftazidime against multiantibiotic-resistant Pseudomonas aeruginosa in an in vitro pharmacodynamic model. Antimicrob Agents Chemother. 2003; 47 905-909
60 Zhanel G G, Craig W A. Pharmacokinetic contributions to postantibiotic effects: focus on aminoglycosides. Clin Pharmacokinet. 1994; 27 377-392
61 Montero A, Ariza J, Corbella X et al.. Efficacy of colistin versus beta-lactams, aminoglycosides, and rifampin as monotherapy in a mouse model of pneumonia caused by multiresistant Acinetobacter baumannii . Antimicrob Agents Chemother. 2002; 46 1946-1952
62 Montero A, Ariza J, Corbella X et al.. Antibiotic combinations for serious infections caused by carbapenem-resistant Acinetobacter baumannii in a mouse pneumonia model. J Antimicrob Chemother. 2004; 54 1085-1091
63 Mahmood I. Allometric issues in drug development. J Pharm Sci. 1999; 88 1101-1106
64 Gales A C, Jones R N, Sader H S. Global assessment of the antimicrobial activity of polymyxin B against 54731 clinical isolates of gram-negative bacilli: report from the SENTRY antimicrobial surveillance programme (2001-2004). Clin Microbiol Infect. 2006; 12 315-321
65 Gilad J, Eskira S, Riesenberg K, Schlaeffer F, Hyam E, Borer A. Emergence of nosocomial colistin-resistant Acinetobacter baumannii. In: 45th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Washington DC; American Society for Microbiology 2005
66 Antoniadou A, Kontopidou F V, Poulakou G et al.. Emerging Colimycin resistant strains of Klebsiella pneumoniae from intensive care unit patients. In: 45th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Washington DC; American Society for Microbiology 2005
67 Li J, Nation R L. Old polymyxins are back, is resistance close?. Clin Infect Dis. 2006; 43 663-664
68 Craig W A. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis. 1998; 26 1-10 quiz 1-2
69 Ambrose P G, Bhavnani S M, Rubino C M et al.. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin Infect Dis. 2007; 44 79-86
70 Li J, Milne R W, Nation R L, Turnidge J D, Coulthard K, Johnson D W. A simple method for the assay of colistin in human plasma, using pre-column derivatization with 9-fluorenylmethyl chloroformate in solid-phase extraction cartridges and reversed-phase high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl. 2001; 761 167-175
71 Li J, Milne R W, Nation R L, Turnidge J D, Coulthard K, Valentine J. Simple method for assaying colistin methanesulfonate in plasma and urine using high-performance liquid chromatography. Antimicrob Agents Chemother. 2002; 46 3304-3307
72 Li J, Milne R W, Nation R L, Turnidge J D, Smeaton T C, Coulthard K. Use of high-performance liquid chromatography to study the pharmacokinetics of colistin sulfate in rats following intravenous administration. Antimicrob Agents Chemother. 2003; 47 1766-1770
73 Coly-Mycin M. Parenteral [package insert]. Mosman, NSW, Australia; Link Medical Products Pty Ltd. 2006
74 Uchino S, Kellum J A, Bellomo R et al.. Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA. 2005; 294 813-818
75 Trotman R L, Williamson J C, Shoemaker D M, Salzer W L. Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy. Clin Infect Dis. 2005; 41 1159-1166
76 Goodwin N J, Friedman E A. The effects of renal impairment, peritoneal dialysis, and hemodialysis on serum sodium colistimethate levels. Ann Intern Med. 1968; 68 984-994
77 Jimenez-Mejias M E, Becerril B, Marquez-Rivas F J, Pichardo C, Cuberos L, Pachon J. Successful treatment of multidrug-resistant Acinetobacter baumannii meningitis with intravenous colistin sulfomethate sodium. Eur J Clin Microbiol Infect Dis. 2000; 19 970-971
78 Jimenez-Mejias M E, Pichardo-Guerrero C, Marquez-Rivas F J, Martin-Lozano D, Prados T, Pachon J. Cerebrospinal fluid penetration and pharmacokinetic/pharmacodynamic parameters of intravenously administered colistin in a case of multidrug-resistant Acinetobacter baumannii meningitis. Eur J Clin Microbiol Infect Dis. 2002; 21 212-214

Roger L NationPh.D.

Facility for Anti-Infective Drug Development and Innovation, Victorian College of Pharmacy, Monash University

381 Royal Parade, Parkville, Victoria 3052, Australia

eMail: Roger.Nation@vcp.monash.edu.au